Eledon ATC Data Shows Sustained Kidney Function and Improved Outcomes with Tegoprubart

What happened

Eledon Pharmaceuticals presented long-term extension results from the Phase 2 BESTOW trial at the American Transplant Congress, demonstrating sustained higher kidney function and improved patient-reported outcomes with tegoprubart compared to tacrolimus. The data showed stable or improving eGFR at 24 months and no late rejection or de novo DSA signals, consistent with prior disclosures. However, the dataset remains small (n~8 in the extension) and the company still needs FDA alignment on a Phase 3 design that avoids a costly eGFR superiority endpoint. The presentation reinforces the CNI-avoidance narrative but does not eliminate the risk that regulators demand a larger, more expensive trial. Investors should focus on the upcoming FDA feedback and Phase 3 protocol lock as the next critical catalysts.

Implication

For investors, the ATC data provides incremental validation that tegoprubart can sustain kidney function and improve quality of life versus tacrolimus, which underpins the platform value. However, the small sample size and lack of granular eGFR curves in the press release warrant skepticism until full data inspection. The key risk remains regulatory: if FDA insists on an eGFR superiority primary endpoint, the Phase 3 cost could force dilutive financing. Conversely, if FDA accepts a composite non-inferiority design, the path to registration becomes cheaper and faster, unlocking significant upside from current levels. The thesis now depends on FDA feedback expected later this year, and any positive signal could drive a re-rating. Position sizing should account for the binary nature of the next 6-12 months.

Thesis delta

The ATC data largely met expectations, confirming the durability signal from prior disclosures and strengthening the argument for a composite Phase 3 endpoint. This shifts the probability slightly toward the bull case, but the stock remains range-bound until FDA alignment is disclosed. The key delta is that the confidence in the clinical data increases, but the regulatory overhang persists unchanged.